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Background: Each day, patients make choices whether or not to take their prescribed 
medications. Previous research has shown that 1 in 7 myocardial infarction (MI) patients 
discontinued thienopyridines within 1 month of receiving a drug-eluting stent (DES) with 
serious consequences. This qualitative research study explored in depth the clopidogrel-taking 
behavior among DES-treated patients who quit taking clopidogrel 1 month after treatment and 
those who continued therapy.
Methods: Sequential patients from a prospective MI registry who reported discontinuing clopi-
dogrel within 30 days of DES treatment (N = 11) were matched with continuers (N = 11). Both 
groups underwent detailed qualitative phone interviews. Coding and thematic representation 
using directed qualitative content analysis by 3 PhD researchers was done.
Results: Patients were 41–77 years old and the majority was Caucasian and male. Multiple 
barriers were described by discontinuers that were not reported by continuers. The most fre-
quently cited barrier was misunderstanding the intended duration of treatment. Discontinuers 
also described system weaknesses that contributed to early discontinuance such as gaps in the 
transition to primary care.
Conclusions: While premature discontinuation of a prescribed therapy is viewed by clinicians 
as a willful disregard for medical advice, early stopping of clopidogrel is inﬂ  uenced greatly by 
processes of care and system issues.
Keywords: medication discontinuance, drug-eluting stent post-care, myocardial infarction
Patients must make choices each day regarding their medications, such as obtaining 
the medication in a timely manner and following dosing instructions (Russell et al 
2006). Consequences of medication nonadherence vary in severity depending upon 
the medication. The American Heart Association (AHA) and American College of 
Cardiology (ACC) have recently recommended continuing thienopyridines (ticlopidine 
and clopidogrel) for a minimum of 12 months after implantation of a drug-eluting 
stent (DES) (Grines et al 2007). These recommendations extend therapy beyond that 
recommended by the FDA-approved package insert and stem from data demonstrat-
ing that stopping antiplatelet therapy prematurely has been associated with subacute 
thrombosis, a frequently fatal complication (Iakovou et al 2005; Eisenstein et al 2007). 
Earlier research indicates that 14% of myocardial infarction (MI) patients in a national 
registry who received a DES after an acute myocardial infarction (AMI) stopped 
thienopyridines within one month of treatment, far short of the FDA-recommended 
6 months and the AHA/ACC-recommended 12 months (Spertus et al 2006). The report 
also demonstrated that these patients were twice as likely to be rehospitalized and nine 
times more likely to die within one year of their DES implantation.
Extensive prior research describes the prevalence and nature of medication 
nonadherence (also known as noncompliance, nonconcordance) (DiMatteo et al 2002). Patient Preferences and Adherence 2008:2 168
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An extreme form of nonadherence is discontinuance, where 
the medication is stopped altogether. Ho and colleagues 
(2006) recently found that 34% of AMI patients discontinued 
at least one prescribed medication within one month of dis-
charge. In another study of acute coronary syndrome (ACS) 
patients, 13%–34% discontinued at least one essential heart 
medication within one year of hospital discharge (Sud et al 
2005). Common reasons cited for stopping medication(s) 
in that study were physician discontinuation and adverse 
effects. However, all previous studies examining reasons 
for medication discontinuation after an ACS have used 
close-ended surveys, which have several important limita-
tions. Preconceived questions and answers restrain response 
options and, therefore, may not capture patients’ primary 
reasons for prematurely stopping medications. In addition, 
data were often collected from a single site, thereby limiting 
the diversity of reasons why patients may stop their medica-
tions. Lastly, noncompliance is frequently conceptualized 
as a problem in decision making, which ignores the role of 
patients’ values and beliefs (Morris and Schulz 1992). To 
overcome these limitations, we conducted a multicenter, 
qualitative research study in which we interviewed two 
groups of patients: discontinuers and continuers of clopido-
grel at 1 month. We investigated why patients prematurely 
stop a life-sustaining medication that doctors feel should be 
continued by comparing the two groups’ perceived barriers 




Patients for this study were recruited from a large prospective 
cohort study, the Translational Research Investigating Under-
lying disparities in acute Myocardial infarction Patients’ 
Health status (TRIUMPH) study. At the time of this study, 
approximately 1000 patients were enrolled in TRIUMPH 
and, approximately half of these had received a DES. In the 
one-month TRIUMPH interview, patients were asked if they 
had stopped taking any prescribed medications since they left 
the hospital for their heart attack. The 1-month follow-up was 
the ﬁ  rst opportunity to assess discontinuance. With regard 
to clopidogrel, professional guidelines indicated a minimal 
duration of 6 months; therefore, no patient receiving a DES 
should have stopped clopidogrel at that early time point.
For the present study, only non-ST elevation myocardial 
infarction (NSTEMI) patients discharged on clopidogrel who 
indicated stopping their clopidogrel within 1 month were 
identiﬁ  ed. Other medications were not studied. The cohort 
was further restricted to those receiving a DES as part of 
their AMI care to insure that the indications for continued 
thienopyridines use were strong. Approval for this study was 
granted from the Saint Luke’s Hospital Institutional Review 
Board prior to contacting any patients.
Between April 2006 and August 2006, 11 patients who 
reported discontinuing clopidogrel were matched by sex and 
education with 11 patients who continued their medication 
within one month of receiving a DES. Continuers and discon-
tinuers were also similar on clinical characteristics. Initially, 
17 patients were identiﬁ  ed as discontinuers and were sent 
letters describing the study. Of those, the interviewer was 
able to contact 13 and 11 consented to be interviewed. A goal 
of qualitative data collection is to reach a level of saturation 
with the topic under study such that the information gained 
from participants becomes redundant, providing no new 
insights into the phenomenon (Marshall 1996). Saturation 
was achieved within the ﬁ  rst 9 interviews and 2 additional 
interviews were conducted to conﬁ  rm that no new concepts 
were being introduced. Two continuers per discontinuer were 
contacted for an interview. Eleven matched continuers were 
ultimately interviewed.
Procedures for collecting interview data
The research team mailed an individualized introductory 
recruitment letter to patients meeting the inclusion criteria 
(NSTEMI DES patients discontinuing or continuing clopi-
dogrel at 1 month). The interviewer then called patients, with 
an average of 1.5 phone call attempts per patient. Telephone 
interviews were recorded, transcribed, and analyzed qualita-
tively. The average interview was 32 minutes in length.
Study materials
Study materials included a recruitment letter for patients, an 
interviewer biography and photo for the patient recruitment 
letter, and a patient interview guide. The letter explained the 
purpose of the study, asked for participation, and provided 
information about the interviewer to increase the likelihood 
that participants would be willing to be interviewed.
To develop the interview guide, we reviewed the exist-
ing literature on thienopyridines as well as relevant medical 
and health psychology literature (Rosenstock 1966; Becker 
1974; Stimson 1974; Janz and Becker 1984; Conrad 1985; 
Morris and Schulz 1992; Bebbington 1995; Bhatt and Topol 
2004; George et al 2005; Iakovou et al 2005; Lewis et al 
2005; Spertus et al 2006). We adapted the Health Belief 
Model (HBM) (Janz and Becker 1984) as a paradigm for 
understanding why and how people make health decisions. Patient Preferences and Adherence 2008:2 169
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An application of this model articulates the decision to take a 
prescribed medicine as a conscious choice driven by patients’ 
beliefs that they can improve their outcomes by taking a medi-
cation or, conversely, that not doing so will result in adverse 
outcomes. Thus the decision to comply with therapeutic 
recommendations stems from a perception that the beneﬁ  ts of 
doing so outweigh the harms of not doing so. This decision to 
continue taking medications is also facilitated by reminders 
and cues to persist with recommended therapies. Previous 
studies have conceptualized noncompliance as a problem 
in medical decision making, but this limited approach can 
ignore the patients’ beliefs and values and the opportunity 
to identify actionable opportunities to improve compliance 
(Morris and Schulz 1992). Therefore, the HBM was used 
as a theoretical framework in developing questions for the 
patient interview guide, though the research team remained 
open to all content from the interviewees (Rosenstock 1966; 
Becker 1974; Janz and Becker 1984). A review of 17 studies 
using the HBM found that ‘perceived barriers’ was the most 
powerful dimension of the model (Janz and Becker 1984; 
Vermeire et al 2001). Thus, we oversampled this domain in 
the interview guide (see Appendix).
Data analysis procedures
The digitally-recorded interview ﬁ  les were transcribed by two 
research assistants. Following transcription, each interview 
was distributed to three Ph.D. researchers who coded the 
interviews. The three researchers reviewed the transcribed 
documents independently to develop a familiarity with the text 
and to search for patterns and themes that occurred frequently 
in a single interview or across interviews. Using this form of 
directed qualitative content analysis, the goal was to extend 
conceptually the HBM when applied to cardiac patients and 
the persistence of clopidogrel (Hsieh and Shannon 2005). The 
data were then manually coded by identifying passages that 
exempliﬁ  ed key concepts or ideas related to the major patterns 
and themes. Throughout the coding process, the researchers 
employed the HBM as the theoretical framework with which 
to understand patients’ perspectives.
The use of multiple coders is important for credible and 
trustworthy data reduction. Preliminary codes were identiﬁ  ed 
and a visual display (afﬁ  nity diagram) of key nodes and attri-
butes was used to organize the reduced narrative data. The 
transcribed interview text was then entered into an electronic 
data analysis program, NVivo (NVivo 2, QSR International, 
Victoria Australia). Use of the computer program provided 
a check of the rigor of the manual coding of the data and 
assisted in organizing the large volume of narrative data.
Assuring rigor during analysis
First, any conclusions that were drawn from the qualitative 
data were reviewed in the context of the entire data set with 
the goal of ﬁ  nding discrepant information. If such information 
was discovered in the review of the data, the conclusions were 
modiﬁ  ed. Second, the investigators worked closely with a 
physician consultant throughout the study to obtain feedback 
on transcript content and consistency with the investigators’ 
conclusions. This reduced the possibility of researcher bias or 
faulty clinical logic. Thirdly, data from multiple interviews 
was collected until data saturation had occurred. Lastly, once 
saturation had occurred, an additional two continuer patients 
and two addtional discontinuer patients were interviewed 
to conﬁ  rm saturation. These patients also served as a form 
of member-checking, a process to validate the conclusions 
drawn by the researchers by discussing conclusions drawn 
from earlier interviews with these patients. Although partici-
pants in qualitative research are fewer in number, the process 
results in much richer, narrative data.
Results
The ﬁ  nal study cohort included 22 AMI patients who had 
similar sociodemographic characteristics (education, sex, 
age, and health insurance coverage) and comorbidities, 
including hypertension, prior heart disease, dyslipidemia, 
and diabetes. Eleven patients were “discontinuers” aged 
45–77; nine (82%) were Caucasian; four (36%) were female; 
and 50% had less than a high school education. Eleven 
patients were “continuers,” matched on sex and education. 
Interviewed continuers were 41–63 years, ﬁ  ve (45%) were 
female, nine (82%) were Caucasian, and ﬁ  ve (45%) had a 
high school education or less. The HBM is comprised of four 
factors: disease severity, susceptibility/threat, barriers, and 
cues to action. These factors emerged clearly as important 
constructs in our analyses. However, discontinuers repeatedly 
described barriers to action and the severity of disease while 
continuers stressed their susceptibility and cues to action. The 
noticeable presence or absence of these themes by discontinu-
ers is presented in Figure 1 (attributes are rank ordered with 
regard to prevalence). The four factors of the HBM provide 
an organizational framework for our analyses.
Severity of disease
This category contains the patient’s perception of the conse-
quences of the condition as serious or not. Whether the patient 
viewed their MI or its subsequent treatment as a signiﬁ  cant 
event and began to internalize the vital changes necessary 
carried over into how they addressed medication taking. Patient Preferences and Adherence 2008:2 170
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A discontinuer patient who reported “Well, I thought it was 
just indigestion,” and thus delayed his treatment, and then 
later determined that he “didn’t need to be taking all this 
medicine”, is very different from a continuer. An example of 
a continuer’s description of their condition: “Yes, I consider it 
serious, yes… I think it is going to limit my life from here.” 
The importance placed on either the signs or symptoms for 
the disease or receiving a diagnosis of myocardial infarc-
tion was interpreted and internalized differently for the two 
groups of patients.
Susceptibility/threat
Susceptibility or threat is reﬂ  ected in a patient’s perception 
of their vulnerability to the condition and implies a defen-
sive or alert strategy. Some discontinuer patients expressed 
a fatalistic approach to their MI believing that no matter 
what they did, they were going to have more heart attacks or 
die from their coronary artery disease. An example of such 
beliefs include the following patient quotes: “Everybody in 
my family has died from a heart attack or cancer. My parents 
both died within the last 4 or 5 years so I was taking care of 
both of them… I’m pretty familiar with it… We’re walking 
dead men.” Denial of their condition is another example of 
this helplessness that is a precursor to patients discontinuing 
their medication. In contrast, continuers routinely described 
how they took their condition seriously and that they didn’t 
want to have another heart attack.
Barriers to action
Discontinuers reported many barriers, whereas continuers 
may have reported a barrier, but then countered with their 
actions to overcome that obstacle. One of the most frequently 
reported barriers was a breakdown in communication which 
in turn lead to poor transitions in care (hospital to outpatient 
or specialist to primary care provider [PCP]). An important 
system-level issue identiﬁ  ed by discontinuers was the lack of 
continuity between inpatient and outpatient care. One patient 
reported “Now when I ﬁ  rst got out, the doctor, I think it was 
clopidogrel, he said I would have to be on it for the rest of 
my life. And when I went to the [PCP] doctor, you know, 
on my return visit, he just said it would be 30 days, and at 
the end of 30 days that was it.”
“DISCONTINUER” PATIENT PERSPECTIVE
SEVERITY OF DISEASE SUSCEPTIBILITY/THREAT
• Failure to recognize signs and 
  symptoms of disease
 • Seen as not serious





BARRIERS TO ACTION CUES TO ACTION
• Lack of care continuity
• Lack of/poor communication




• Unhealthy lifestyle choices
• Economic burden
• Lack of knowledge
• Personal health feelings and 
  beliefs
• Lack of effective communication
• Unaware of cardiac rehabilitation
• Lack of prompts from family 
  and friends
• Missed general cues
Figure 1 Discontinuer patient ﬁ  ndings (Factors and attributes).Patient Preferences and Adherence 2008:2 171
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Correspondingly, an obvious distinction between 
discontinuers and continuers was that continuers did not 
report extensive gaps in their care. One continuer said he 
sees his heart doctor only once a year but “he still sends 
me letters like, you know it’s time for your cholesterol, it’s 
time for your sugar diabetes check, you know. He updates 
me on everything that I need to do. Then I got to go to my 
primary care and take it to him and he does all the tests and 
that stuff and sends the results back to my heart doctor.” This 
type of communication that provides a connection between 
specialists and primary care physicians was not described in 
discontinuer patient interviews.
Another difﬁ  cult transition in care occurred when patients 
were geographically distant from the treatment center. The 
breakdown in communication and the distance with which 
a patient would need to travel sometimes precluded special-
ized follow-up. The discontinuer patients frequently reported 
struggling with relaying speciﬁ  c information to their primary 
care providers such as treatments received and new medica-
tions added. Discontinuers also stated that their local primary 
care physicians were not always familiar with the distant 
specialists and the specialist’s intended treatment plan. From 
comments made by discontinuers, if information regarding 
medication and recovery instructions was conveyed to the 
patient, he or she frequently interpreted it incorrectly or did 
not recall having received the information.
Poor communication beyond the transition of care 
was also an independent barrier for some patients. 
Several discontinuers reported feeling limited by the time 
available for seeking information from caregivers during 
hospital discharge and later during follow-up visits. A 
few continuers reported similar experiences, but then 
identiﬁ  ed other sources that they used for gaining more 
information. Another difﬁ  culty reported by discontinuers 
and identiﬁ  ed by the researchers was fragmentation in 
care created by multiple clinicians attending to a patient. 
For example, patients reported receiving contradictory 
information from clinicians; however, continuers reported 
seeking clariﬁ  cation, whereas discontinuers did not. A 
priori, cost was expected to be a frequently reported 
reason for discontinuing clopidogrel early. Surprisingly, 
difﬁ  culty affording the medication, or economic burden, 
was not a commonly described barrier by patients. Though 
one female discontinuer stated “The ﬁ  rst time around, 
I got Medicaid from the social services here because I 
had an un-raised child in the house with me. Well he’s 
20 years old now. And that cut it off. That cut the Medicaid 
off. That’s why I quit taking it.” Not surprisingly, when 
continuers reported cost as a potential barrier to clopidogrel 
continuance, they also described strategies to overcome it. 
For example, one patient remembered “the doctor told me 
if I can’t afford it, you know, because it is expensive, to 
let them know, and they would do what they can to get it 
for me for free.”
As anticipated, some discontinuer patients reported self-
medicating by simply deciding to stop taking clopidogrel 
because they felt they no longer needed the medication 
(felt better or worse or that it resulted in no effect) or they 
perceived they were having unpleasant side effects (fatigue, 
rash, bleeding, bruising). They also reported stopping clopi-
dogrel because they believed it was similar to other blood 
thinners, such as coumadin® and aspirin, and didn’t see 
the value in being on duplicate medications. Such barriers 
were not reported by patients who continued taking their 
clopidogrel.
Cues to action
The largest single difference between the discontinuers and 
the continuers was that the majority of continuers could 
recall having received education or information speciﬁ  cally 
on clopidogrel. One patient described the hospital discharge 
process as a cue to action: “Yeah. And they explained to me 
what they [medications] were and what they were for. Like 
on the clopidogrel they stressed the importance of taking 
[it].” The most frequent message among discontinuers, 
however, was that they were unaware they should be taking 
clopidogrel.
Discontinuers frequently were unable to recall receiv-
ing education about the medicine or clopidogrel’s speciﬁ  c 
purpose. Another important cue to action is whether the 
post-DES patient was aware of the intended duration for 
clopidogrel. Continuers reported knowing the duration for 
clopidogrel in contrast to discontinuers who did not know 
or were uncertain about duration. Several continuer patients 
reported that they would be taking the drug for a year, while 
one patient said “Well yeah I ask them and they said I may 
be taking it for the rest of my life.”
Continuers could easily recall having heard about their 
clopidogrel medication, including the purpose and speciﬁ  cally 
the duration. In addition, several described communications 
between their hospital physicians or cardiologists and their 
regular primary care physician. The consistency between 
interview findings for continuers pointed to knowledge 
received about the medication, its purpose and duration, which 
led the patient to assign value to continuing medications, and 
in this case, clopidogrel.Patient Preferences and Adherence 2008:2 172
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Discussion
Interventional cardiologists who implant DES uniformly 
believe that it is imperative that the patients continue thi-
enopyridines after discharge, due to the potential fatal conse-
quences from premature discontinuation (Iakovou et al 2005; 
Eisenstein et al 2007; Grines et al 2007). After interviewing 
both discontinuers and continuers, we identiﬁ  ed a number 
of themes that distinguished discontinuers and continuers. 
These included multiple barriers that were reported by dis-
continuers, but not continuers; clarity of knowledge about 
clopidogrel purpose and duration; and system-level issues 
that were obstacles for discontinuers such as transition of 
care from in-patient to out-patient.
Review of prior studies examining medication noncom-
pliance identiﬁ  ed weaknesses in the nature or design of these 
studies. First, an implicit assumption is often made that the 
patient is a passive, obedient, and unquestioning recipient of 
medical instructions (Stimson 1974; Conrad 1985). Second, 
many studies focus upon what was wrong with the patient 
that led to their noncompliance (Bebbington 1995). Third, 
previous researchers have noted that “very little attention has 
been paid to the patient’s perspectives of adherence” (George 
et al 2005, p 3199). The ﬁ  ndings of our study support the 
HBM, in which the patient ﬁ  rst perceives a health threat 
that may then cue the patient to take action. The impact of 
patients’ perception of barriers on discontinuing clopidogrel 
is consistent with the ﬁ  nding of Janz and Becker (1984) that 
‘perceived barriers’ is the most powerful dimension of the 
HBM. Some patients reported discontinuing medications 
for a variety of barrier-type reasons, such as not believing in 
taking medications, not recalling education on clopidogrel 
purpose or duration, perceiving unlikely side effects (eg, 
fatigue) or experiencing real side effects, and maintaining 
generally unhealthy lifestyles. Economic burden, while an 
obstacle for some patients, was not a commonly described 
barrier. Conversely, continuers could describe barriers, but 
identiﬁ  ed more beneﬁ  ts and cues to action, thus, overcoming 
most barriers.
A recent article reported an observational study of 
physician and patient surveys surrounding new medication 
prescription communication and found that while 74% of the 
new prescriptions were identiﬁ  ed by name to the patient, only 
34% of the time was the intended duration of the medication 
communicated (Tarn et al 2006). This is consistent with our 
ﬁ  ndings in that several patients who discontinued clopido-
grel responded that they were not supposed to be taking the 
medicine when asked why they had stopped taking it. This 
gap in communication highlights a need for clearer patient 
education at discharge and during early follow-up regarding 
clopidogrel treatment duration.
Gaps in transitions of care were identiﬁ  ed as a major 
obstacle and breakdown in processes that could sustain 
medication-taking behavior. Kripalani and colleagues (2007) 
recently published a review of studies on communication 
between hospital-based and primary care physicians. They 
identiﬁ  ed 73 studies on information deﬁ  cits or interven-
tions designed to improve the information hand-off. The 
conclusion was that deﬁ  cits adversely affected patient care, 
especially the transition from hospital discharge to outpatient 
follow-up care. Our ﬁ  ndings, on an individual patient level, 
conﬁ  rm the difﬁ  culty of this transitional time. Additionally, 
medication reconciliation problems were evident in patients’ 
portrayals of their experience with their MI and medication 
continuance. The healthcare system seems to fail in suf-
ﬁ  ciently educating many patients who are discharged on 
clopidogrel following DES and thus the need for customized 
or more patient-friendly material is necessary, especially 
stressing duration of clopidogrel.
This study has some limitations. The sample size is 
small; however, the richness of the data and the attainment 
of saturation in the present study indicate a sufﬁ  cient number 
of patients to make the results credible, trustworthy, and 
meaningful. Furthermore, as with any study using a patient 
registry, the patients drawn from this national AMI registry 
may not be representative of all AMI patients or even of typi-
cal AMI patients. In addition, qualitative data analysis relies 
on researcher interpretations with the potential for bias. In the 
present study, multiple reviewers from different disciplines 
(nursing, psychology, and anthropology) analyzed the data 
and discussed the ﬁ  ndings with clinicians from other disci-
plines (medical doctors and patient interviewers). Lastly, a 
technique called member checking, which takes preliminary 
ﬁ  ndings back to similar subjects for accuracy of conclusions 
drawn, was used to assure the trustworthiness of the research-
ers’ interpretations.
In conclusion, rather than representing a negative patient 
behavior, our study suggests that early stopping of clopido-
grel is inﬂ  uenced greatly by healthcare processes. Second 
only to education, system-level issues such as lack of conti-
nuity between inpatient and outpatient care were identiﬁ  ed 
as common problems among discontinuers, but not among 
continuers of clopidogrel therapy. Continuers consistently 
described having received information and knowledge about 
clopidogrel’s purpose, beneﬁ  ts, and duration. Future research 
should explore the efﬁ  cacy of interventions to improve con-
tinuance, such as efforts that increase patients’ awareness Patient Preferences and Adherence 2008:2 173
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of medication indication and duration, clinician short and 
longer-term telephonic follow-up, providing the patient with 
the recommended number of pills in the same packaging as 
the DES, and changes in hospital discharge medication forms 
to include a duration column. These qualitative ﬁ  ndings 
should be considered exploratory in nature and could be 
well utilized as the foundation for future quantitative work 
seeking to develop a tool to identify patients at risk for 
premature medication discontinuance. Thus, identifying 
barriers and factors that promote better transitions of care 
can be the ﬁ  rst step towards aligning clinician and patient 
beliefs for post-MI and post-DES care to avert potentially 
fatal consequences.
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Appendix
Interview guide: Core questions and probe items for patients
Background information
1. Would you please tell me a little bit about your experience 
with your heart attack?
  a. What was it like?
  b.  How did it happen and what prompted you to go to the 
hospital?
  c. What were the events involved?
2. Please tell me about your experience when you were 
discharged from the hospital.
  a. What was good and bad about the experience?
  b.  When you were discharged from the hospital, who gave 
you instructions for taking your medications – the doc-
tor, the nurse, or some other hospital staff person?
  c.  Who provided information about your medications and 
other healthcare matters?
  d.   In what ways were you involved in the discharge 
process? How did you participate or what did you do?
3. When you were discharged from the hospital could you 
identify the medications you were prescribed?
  a.  If not at the time, do you now know what each medica-
tion does for you?
  b.   Who or what materials provided the best information 
for you to understand your medications?
4. Since experiencing your heart condition, and returning 
home from the hospital, how have you been feeling? 
How are you feeling today?
Reasons for discontinuing
1. In your 1-month TRIUMPH interview, you indicated that 
you stopped taking certain medications. We are particu-
larly interested in why people might stop taking Plavix. 
Would you talk about your reasons for discontinuing use 
of that medicine?
  a.   Can you tell me why Plavix was prescribed to you? 
Why is it supposed to be beneﬁ  cial to you?
  b.   What other medications have you stopped taking and 
why have you stopped taking them?
  c.   What person(s), procedures, processes, or materials 
would better help you understand the purpose of your 
medications?
  d.   From your unique perspective, what would make it 
easier for you to continue taking the medications, 
particularly Plavix?
Economic Burden and Insurance (depending on patient 
ﬁ  nancial/insurance data points from TRIUMPH, certain 
questions may not be necessary)
2. How much of a ﬁ  nancial burden is it to you with or without 
your insurance?
3.   Do you have insurance that helps pay for the medications –
I am thinking speciﬁ  cally of Plavix?
  a.   Please tell me about your experiences when working 
with your insurance company? In what ways is it easy 
or difﬁ  cult?
  b.  (DEPENDING ON THE ABOVE RESPONSE) From 
your perspective, what would make it easier to work 
with the insurance company to ensure your healthcare 
needs are met?
Healthcare system
4. Given your current experiences with the healthcare indus-
try, please tell me why you think they are doing the best 
that they can or not doing the best that they can for you 
and others like you.
  a.   Why do you feel as though you can or cannot openly 
share your medical problems and concerns with your 
doctor about your medical treatment and progress?
  b.   Why do you feel as though you can or cannot openly 
share your medical problems and concerns with 
your pharmacist about your medical treatment and 
progress?
Threat/susceptibility
1. Why would you say that your heart condition is a serious 
matter or not?
2. In what ways do you believe that your heart condition 
affects your day-to-day life now?
  a.   In what ways do you think it will affect you in the 
future?
3. What do you think caused your heart attack?
  a. Do you know why a heart attack happens?
  b.   What are the conditions that exist within you – your 
arteries and heart that cause a heart attack?
Cues
1. Who or what provided the best information for you to 
understand your heart condition and the reasons for your 
heart attack?
  a.   What person(s), procedures, processes, or materials 
would better help you understand the causes of your 
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2. DEPENDING ON THE PATIENT TRIUMPH DATA 
POINT REGARDING SOCIAL SUPPORT:
  Do you have family, friends, neighbors, or anyone else 
who stops by regularly (eg, daily, weekly) to check up on 
you and to ensure that you are taking your medications 
and simply just doing well?
Note: Patients will be prompted to expand on responses 
with questions like “Could you tell me more about that?” 
or “How so?”